Immune-mediated agranulocytosis caused by the cocaine adulterant levamisole: A case for reactive metabolite(s) involvement

Drug Metabolism and Disposition

Volumn 40, Issue 6, 2012, Pages 1067-1075

  Wolford, Angela ^a   McDonald, Thomas S ^a   Eng, Heather ^a   Hansel, Steven ^a   Chen, Yue ^a   Bauman, Jonathan ^a   Sharma, Raman ^a   Kalgutkar, Amit S ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,5,6 TETRAHYDROIMIDAZO[2,1 B]THIAZOLE; AMINOREX; CAPTOPRIL; COCAINE; DEXAMISOLE; EUGENOL; FLUOROURACIL; HLA B27 ANTIGEN; IMIDAZO[2,1 B]THIAZOLE DERIVATIVE; LEVAMISOLE; METIAMIDE; PENICILLAMINE; PROPYLTHIOURACIL; REACTIVE OXYGEN METABOLITE; TETRAMISOLE; THIAMAZOLE; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; AGRANULOCYTOSIS; AMYOTROPHIC LATERAL SCLEROSIS; AREA UNDER THE CURVE; AUTOIMMUNE DISEASE; BLOOD DISEASE; BLOOD DYSCRASIA; BREAST CANCER; CAUSAL ATTRIBUTION; CHILDHOOD DISEASE; COCAINE DEPENDENCE; COLON CANCER; COLORECTAL CANCER; DELAYED HYPERSENSITIVITY; DISEASE ASSOCIATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTAMINATION; DRUG DESIGN; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG USE; DRUG WITHDRAWAL; GRAVES DISEASE; HEMATOLOGIC DEPRESSION; HEPATITIS B; HUMAN; HYPERTENSION; IMMUNE MEDIATED INJURY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; KIDNEY CLEARANCE; LEUKOPENIA; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MOOD CHANGE; NECROTIZING ARTERITIS; NEOPLASM; NEPHRITIS; NEPHROTIC SYNDROME; NONHUMAN; PARASITOSIS; PEPTIC ULCER; PLASMA CLEARANCE; PRIORITY JOURNAL; RASH; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; SYSTEMIC DISEASE; TOXICITY TESTING; ULCERATIVE COLITIS;

AGRANULOCYTOSIS; ANIMALS; COCAINE; DRUG CONTAMINATION; HUMANS; LEVAMISOLE; UNITED STATES; UNITED STATES PUBLIC HEALTH SERVICE; VETERINARY DRUGS;

EID: 84862104673     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.045021     Document Type: Review

References (60)

1. Adams JG (1978) Pharmacokinetics of levamisole. J Rheumatol Suppl 4:137-142.
2. Albonico M, Bickle Q, Ramsan M, Montresor A, Savioli L, and Taylor M (2003) Efficacy of mebendazole and levamisole alone or in combination against intestinal nematode infections after repeated targeted mebendazole treatment in Zanzibar. Bull World Health Organ 81:343-352. (Pubitemid 36644260)
3. Amann FW, Buhler FR, Conen D, Brunner F, Ritz R, and Speck B (1980) Captopril-associated agranulocytosis. Lancet 1:150.
4. Amery WK and Butterworth BS (1983) The dosage regimen of levamisole in cancer: is it related to efficacy and safety? Int J Immunopharmacol 5:1-9. (Pubitemid 13144332)
5. Amery WK and Bruynseels JP (1992) Levamisole, the story and the lessons. Int J Immunopharmacol 14:481-486.
6. Bertol E, Mari F, Milia MG, Politi L, Furlanetto S, and Karch SB (2011) Determination of aminorex in human urine samples by GC-MS after use of levamisole. J Pharm Biomed Anal 55:1186-1189.
7. Bharadwaj M, Illing P, Theodossis A, Purcell AW, Rossjohn J, and McCluskey J (2012) Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annu Rev Pharmacol Toxicol 52:401-431.
8. Bloom JC, Lewis HB, Sellers TS, and Deldar A (1987) The hematological effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man. Toxicol Appl Pharmacol 90:135-142.
9. Buchanan JA, Oyer RJ, Patel NR, Jacquet GA, Bornikova L, Thienelt C, Shriver DA, Shockley LW, Wilson ML, Hurlbut KM, et al. (2010) A confirmed case of agranulocytosis after use of cocaine contaminated with levamisole. J Med Toxicol 6:160-164.
10. Buchanan JA, Vogel JA, and Eberhardt AM (2011) Levamisole-induced occlusive necrotizing vasculitis of the ears after use of cocaine contaminated with levamisole. J Med Toxicol 7:83-84.
11. Casale JF, Corbeil EM, and Hays PA (2008) Identification of levamisole impurities found in illicit cocaine exhibits. DEA Resources, Microgram Journal 6:82-89.
12. Chang A, Osterloh J, and Thomas J (2010) Levamisole: a dangerous new cocaine adulterant. Clin Pharmacol Ther 88:408-411.
13. Cooper DS, Goldminz D, Levin AA, Ladenson PW, Daniels GH, Molitch ME, and Ridgway EC (1983) Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med 98:26-29. (Pubitemid 13217959)
14. De Brabander M, De Cre'e J, Vandebroek J, Verhaegen H, and Janssen PA (1992) Levamisole in the treatment of cancer: anything new? (Review). Anticancer Res 12:177-187.
15. Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Andersson M, Kamby C, Knoop AS, and Danish Breast Cancer Cooperative Group (2010) Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer. Cancer 116:2081-2089.
16. Forrest JA, Shearman DJ, Spence R, and Celestin LR (1975) Letter: neutropenia associated with metiamide. Lancet 1:392-393.
17. Gaine SP, Rubin LJ, Kmetzo JJ, Palevsky HI, and Traill TA (2000) Recreational use of aminorex and pulmonary hypertension. Chest 118:1496-1497.
18. Goldin A, Chirigos MA, Macdonald JS, Fefer A, and Mihich E (1982) Biologic-response modifiers and adjuvant chemotherapy: consideration of selected preclinical investigations in relation to clinical potential. Recent Results Cancer Res 80:351-356.
19. Greenspan EM and Erlich R (1991) Levamisole and the new era of chemoimmunotherapy. Cancer Invest 9:111-124.
20. Hofstra AH and Uetrecht JP (1993) Myeloperoxidase-mediated activation of xenobiotics by human leukocytes. Toxicology 82:221-242.
21. Hodinka L, Géher P, Merétey K, Gyódi EK, Petrányi GG, and Bozsóky S (1981) Levamisole-induced neutropenia and agranulocytosis: association with HLA B27 leukocyte agglutinating and lymphocytotoxic antibodies. Int Arch Allergy Appl Immunol 65:460-464. (Pubitemid 11078378)
22. Hodson E (2003) The management of idiopathic nephrotic syndrome in children. Paediatr Drugs 5:335-339.
23. Ibáñez L, Vidal X, Ballarín E, and Laporte JR (2005) Population-based drug-induced agranulocytosis. Arch Intern Med 165:869-874. (Pubitemid 40563233)
24. Janssen PA (1976) The levamisole story. Prog Drug Res 20:347-383.
25. Kean WF, Dwosh IL, Anastassiades TP, Ford PM, and Kelly HG (1980) The toxicity pattern of D-penicillamine therapy. A guide to its use in rheumatoid arthritis. Arthritis Rheum 23:158-164. (Pubitemid 10164321)
26. Kouassi E, Caillé G, Léry L, Larivière L, and Vézina M (1986) Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine. Biopharm Drug Dispos 7:71-89. (Pubitemid 16155186)
27. Koyama K, Oishi T, Ishii A, and Deguchi T (1983) Metabolic fate of levamisole in rats, dogs and monkeys. Pharmacometrics (Tokyo) 26:869-876. (Pubitemid 14167694)
28. Lai WG, Zahid N, and Uetrecht JP (1999) Metabolism of trimethoprim to a reactive iminoquinone methide by activated human neutrophils and hepatic microsomes. J Pharmacol Exp Ther 291:292-299. (Pubitemid 29451602)
29. 14C]-propylthiouracil in human polymorphonuclear leukocytes. Drug Metab Dispos 7:285-289.
30. Lee E, Miki Y, Katsura H, and Kariya K (1990) Mechanism of inactivation of myeloperoxidase by propylthiouracil. Biochem Pharmacol 39:1467-1471. (Pubitemid 20122584)
31. Lorenz M, Evering WE, Provencher A, Blue JT, Lewis HB, Hazelette JR, Rajagopalan P, Meunier PC, and Car BD (1999) Atypical antipsychotic-induced neutropenia in dogs. Toxicol Appl Pharmacol 155:227-236. (Pubitemid 29153370)
32. Macfarlane DG and Bacon PA (1978) Levamisole-induced vasculitis due to circulating immune complexes. Br Med J 1:407-408. (Pubitemid 8318798)
33. Mielants H and Veys EM (1978) A study of the hematological side effects of levamisole in rheumatoid arthritis with recommendations. J Rheumatol Suppl 4:77-83. (Pubitemid 9068469)
34. Migdalof BH, Antonaccio MJ, McKinstry DN, Singhvi SM, Lan SJ, Egli P, and Kripalani KJ (1984) Captopril: pharmacology, metabolism and disposition. Drug Metab Rev 15:841-869.
35. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, et al. (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122:321-326.
36. Parkinson DR, Cano PO, Jerry LM, Capek A, Shibata HR, Mansell PW, Lewis MG, and Marquis G (1977) Complications of cancer immunotherapy with levamisole. Lancet 1:1129-1132. (Pubitemid 8111079)
37. Pichler W, Yawalkar N, Schmid S, and Helbling A (2002) Pathogenesis of drug-induced exanthems. Allergy 57:884-893.
38. Pillans PI and Koopowitz A (1991) Captopril-associated agranulocytosis. A report of 3 cases. S Afr Med J 79:399-400.
39. Pohl LR, Satoh H, Christ DD, and Kenna JG (1988) The immunologic and metabolic basis of drug hypersensitivities. Annu Rev Pharmacol Toxicol 28:367-387.
40. Roberts G (1994) Levamisole, in WHO Food Additives Series 33: Toxicological evaluation of certain veterinary drug residues in food. pp 805, World Health Organization (WHO), Canberra, Australia.
41. Rongioletti F, Ghio L, Ginevri F, Bleidl D, Rinaldi S, Edefonti A, Gambini C, Rizzoni G, and Rebora A (1999) Purpura of the ears: a distinctive vasculopathy with circulating autoantibodies complicating long-term treatment with levamisole in children. Br J Dermatol 140:948-951. (Pubitemid 29238474)
42. Sayo H and Saito M (1991) Hydrogen peroxide-dependent oxidation metabolism of 1-methyl-2-mercaptoimidazole (methimazole) catalysed by myeloperoxidase. Xenobiotica 21:1217-1224.
43. Schnieden H (1981) Levamisole-a general pharmacological perspective. Int J Immunopharmacol 3:9-13.
44. Shu YZ, Kingston DG, Van Tassell RL, and Wilkins TD (1991) Metabolism of levamisole, an anti-colon cancer drug, by human intestinal bacteria. Xenobiotica 21:737-750.
45. Symoens J, Veys E, Mielants M, and Pinals R (1978) Adverse reactions to levamisole. Cancer Treat Rep 62:1721-1730. (Pubitemid 9132928)
46. Symoens J, De Cree J, Van Bever WFM, and Janssen PAJ (1979) Pharmacological and Biochemical Properties of Drug Substances. Vol. 2, American Pharmacology Association of the Academy of Pharmacological Science, Washington DC.
47. Thompson D, Constantin-Teodosiu D, Norbeck K, Svensson B, and Moldéus P (1989) Metabolic activation of eugenol by myeloperoxidase and polymorphonuclear leukocytes. Chem Res Toxicol 2:186-192. (Pubitemid 19159949)
48. Ullrich K, Koval R, Koval E, Bapoje S, and Hirsh JM (2011) Five consecutive cases of a cutaneous vasculopathy in users of levamisole-adulterated cocaine. J Clin Rheumatol 17:193-196.
49. Uetrecht JP (1992) The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metab Rev 24:299-366.
50. Umeki S, Konishi Y, Yasuda T, Morimoto K, and Terao A (1985) D-penicillamine and neutrophilic agranulocytosis. Arch Intern Med 145:2271-2272.
51. Waldhauser L and Uetrecht J (1991) Oxidation of propylthiouracil to reactive metabolites by activated neutrophils. Implications for agranulocytosis. Drug Metab Dispos 19:354-359.
52. Waller PJ (2006) From discovery to development: current industry perspectives for the development of novel methods of helminth control in livestock. Vet Parasitol 139:1-14.
53. Waller JM, Feramisco JD, Alberta-Wszolek L, McCalmont TH, and Fox LP (2010) Cocaine-associated retiform purpura and neutropenia: is levamisole the culprit? J Am Acad Dermatol 63:530-535.
54. Walsh NM, Green PJ, Burlingame RW, Pasternak S, and Hanly JG (2010) Cocaine-related retiform purpura: evidence to incriminate the adulterant, levamisole. J Cutan Pathol 37:1212-1219.
55. Watson AD, Sangster NC, Church DB, and Van Gogh H (1988) Levamisole pharmacokinetics and bioavailability in dogs. Res Vet Sci 45:411-413.
56. Wilkin JK, Hammond JJ, and Kirkendall WM (1980) The captopril-induced eruption. A possible mechanism: cutaneous kinin potentiation. Arch Dermatology 116:902-905. (Pubitemid 10039130)
57. Woestenborghs R, Michielsen L, and Heykants J (1981) Determination of levamisole in plasma and animal tissues by gas chromatography with thermionic specific detection. J Chromatogr 224:25-32. (Pubitemid 11006742)
58. Yeung JH, Breckenridge AM, and Park BK (1983) Drug protein conjugates-VI. Role of glutathione in the metabolism of captopril and captopril plasma protein conjugates. Biochem Pharmacol 32:3619-3625. (Pubitemid 14205374)
59. Young R (1992) Aminorex produces stimulus effects similar to amphetamine and unlike those of fenfluramine. Pharmacol Biochem Behav 42:175-178.
60. Zhu NY, Legatt DF, and Turner AR (2009) Agranulocytosis after consumption of cocaine adulterated with levamisole. Ann Intern Med 150:287-289.